CA125 is widely used as a marker in three separate clinical cases, in which it is considered as a screening test for the early diagnosis of ovarian cancer, to distinguish benign from malignant disease in pre-and postmenopausal women with pelvic masses, and finally to track the therapeutic response in ovarian cancer patients [28]. This evidence concerns the gene MUC16 and ovarian carcinoma.